Ad
related to: monoclonal antibody treatment prostate cancer results explained pictures- Downloadable Resources
Browse Helpful Resources
for Patients and Caregivers.
- FAQs
Find Answers to Commonly
Asked Questions from Patients.
- Financial Assistance Info
Learn About Financial Support
Options for Eligible Patients.
- Clinical Glossary
Need Help Decoding Medical Words?
Our Clinical Glossary Can Help.
- Downloadable Resources
Search results
Results from the WOW.Com Content Network
It binds to the epithelial cell adhesion molecule (EpCAM - CD326), with the intent to trigger antibody-dependent cellular cytotoxicity. It was developed by Micromet Inc, which was acquired by Amgen. [1] Adecatumumab has been used in clinical studies of treatment in colorectal, prostate [2] and breast cancers. [3] Phase II results were published ...
The remaining syllables of the INNs, as well as the column Source, are explained in Nomenclature of monoclonal antibodies. Types of monoclonal antibodies with other structures than naturally occurring antibodies. The abbreviations in the column Type are as follows: mab: whole monoclonal antibody; Fab: fragment, antigen-binding (one arm)
Capromab is a mouse monoclonal antibody which recognizes a protein found on both prostate cancer cells and normal prostate tissue. It is linked to pendetide , a derivative of DTPA . [ 2 ] Pendetide acts as a chelating agent for the radionuclide indium-111 .
Obinutuzumab has two black box warnings: hepatitis B reactivation and progressive multifocal leukoencephalopathy. [7] [5]In the clinical trial of obinutuzumab in combination with chlorambucil, participants experienced infusion reactions (69%; 21% grade 3/4), neutropenia (40%; 34% grade 3/4), thrombocytopenia (15%; 11% grade 3/4), anemia (12%), and pyrexia and cough (10% each).
Antibody-directed enzyme prodrug therapy (ADEPT) involves the application of cancer-associated monoclonal antibodies that are linked to a drug-activating enzyme. Systemic administration of a non-toxic agent results in the antibody's conversion to a toxic drug, resulting in a cytotoxic effect that can be targeted at malignant cells.
One possible treatment for cancer involves monoclonal antibodies that bind only to cancer-cell-specific antigens and induce an immune response against the target cancer cell. Such mAbs can be modified for delivery of a toxin , radioisotope , cytokine or other active conjugate or to design bispecific antibodies that can bind with their Fab ...
Monoclonal antibodies: designed to bind to specific targets on cancer cells, marking cancer cells so that they will be better seen and destroyed by the immune system. Treatment vaccines : also known as therapeutic cancer vaccines, help the immune system learn to recognize and react to mutant proteins specific to the tumor and destroy cancer ...
It is a recombinant humanized monoclonal antibody of the immunoglobulin IgG1 subclass against the interleukin-6 receptor (IL-6R). [18] Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer.
Ad
related to: monoclonal antibody treatment prostate cancer results explained pictures